HUTCHMED (China) Limited
NASDAQ: HCM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Chig Fung Cheng
- Employees
- 1,811
- Headquarters
- Hong Kong, Hong Kong SAR China
- IPO year
- 2016
- Market cap
- $1.8B
- Website
- https://www.hutch-med.com
Loading HCM…
Loading profile data…Frequently asked questions about HCM
What does HUTCHMED (China) Limited (HCM) do?
HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related disorders. Its operations are divided into two main areas: Oncology/Immunology and a segment encompassing Other Ventures. The company's reach extends...
Where does HCM trade?
HUTCHMED (China) Limited (HCM) trades on the NASDAQ Global Select.
What sector is HCM in?
HUTCHMED (China) Limited (HCM) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of HUTCHMED (China) Limited?
Chig Fung Cheng is the chief executive officer of HUTCHMED (China) Limited (HCM).
Where is HUTCHMED (China) Limited headquartered?
HUTCHMED (China) Limited is headquartered in Hong Kong SAR China.
Does HCM pay a dividend?
HUTCHMED (China) Limited (HCM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did HCM go public?
HUTCHMED (China) Limited (HCM) completed its initial public offering in 2016.
Is HCM an ADR?
Yes — HCM is an American Depositary Receipt; its underlying shares trade on a non-US exchange. HUTCHMED (China) Limited reporting and dividends follow the underlying issuer.